In a post hoc analysis of the LIBERTY ASTHMA QUEST study, researchers found that dupilumab may reduce exacerbations in patients with allergic bronchopulmonary aspergillosis.
Among patients with severe asthma, benralizumab treatment improved nasal symptoms, which worsen with increasing baseline blood eosinophil count.
In a real-world setting, mepolizumab therapy significantly reduced the rate of asthma exacerbations and their related costs.
Children with a family history of cancer may be more likely to develop childhood asthma.
Ragweed sublingual immunotherapy tablet improved symptoms and decreased the need for rescue medication in the largest allergy immunotherapy trial in children with ragweed allergic rhinitis with or without conjunctivitis.
High-dose peanut oral immunotherapy provided similar or greater efficacy than other previously reported forms of peanut oral immunotherapy without additional safety concerns.
Fractional exhaled nitric oxide values may help in the identification of cough variant asthma in patients with chronic cough.
Budesonide oral suspension was associated with improvements in dysphagia in patients with eosinophilic esophagitis.
Mepolizumab was associated with reductions in eosinophil levels and asthma exacerbations,as well as improvements in quality of life in uncontrolled severe eosinophilic asthma.
Asthma plus atopic dermatitis may lead to poorer sleep-specific outcomes in pediatric patients.